Decentralized Dietary UC Pilot Trial

NCT ID: NCT02357537

Last Updated: 2015-11-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31

Brief Summary

This study is designed to assess differences in remote and on-site patient study participation in the State of Massachusetts, as well as the significance of dietary interventions and their impact on UC. The study will activate one site with a Principal Investigator who will utilize each subject's local care system (local Gastroenterologist) to collect study data, along with telemonitoring and video visits, to make key study assessments and decisions regarding subjects' progression in the study.

Conditions

Colitis, Ulcerative

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: DOUBLE

Study Groups

Traditional

Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).

Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice).

Group Type: ACTIVE_COMPARATOR

Combined Anti-inflammatory Diet (CAID)

Intervention Type: BEHAVIORAL

The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.

Remote

Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.

Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice).

Group Type: ACTIVE_COMPARATOR

Combined Anti-inflammatory Diet (CAID)

Intervention Type: BEHAVIORAL

The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.

Interventions

Combined Anti-inflammatory Diet (CAID)

The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

1. Males and females between the ages of 18 and 80, inclusive, who reside in the state of Massachusetts.

2. Ability and willingness to provide documented informed consent and to comply with the study procedures, including in-person visits for Arm 1 and video visits for Arm 2.

3. Documented history of moderate to severe active UC

4. Disease duration of ≥12 weeks at the time of screening (diagnosed according to American College of Gastroenterology practice guidelines)

5. Screening fecal calprotectin>350 mg/g

6. Diagnosis of moderately to severely active UC, including historical endoscopy sub score ≥2; a rectal bleeding sub score ≥1 and disease activity a minimum of 25 cm from the anal verge.

7. Documented (via video or report) endoscopy performed within 2 years prior to randomization.

8. Access to a computer or mobile device with internet connection and an active email address.

Exclusion Criteria

1. Prior extensive colonic resection, subtotal or total colectomy or planned surgery for UC

2. Past or present ileostomy or colostomy

3. Short bowel syndrome

4. Diagnosis of indeterminate colitis, fulminant colitis, toxic megacolon

5. Past or present fistula or abdominal abscess

6. History or current evidence of colonic mucosal dysplasia

7. Use of tube feeding, defined formula diets or parenteral alimentation/nutrition which has not been discontinued ≥3 weeks prior to study enrollment

8. Use of anticoagulants, herbal supplements and omega-3/fish oil supplements during the study

9. Crohn's Disease

10. Significant uncontrolled co-morbidity, such as neurological, cardiac (e.g., moderate to severe heart failure NYHA class III/IV), pulmonary, renal, hepatic, endocrine or gastrointestinal disorders

11. History of alcohol, drug or chemical abuse within 6 months prior to screening

12. Pregnant females, those intending to become pregnant, and those who are lactating

13. Current participation in any other clinical trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Transparency Life Sciences

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tomasz Sablinski, MD, PhD

Role: STUDY_DIRECTOR

Transparency Life Sciences

Locations

Crohn's and Colitis Center at Brigham and Women's Hospital

Brookline, Massachusetts, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Justine States

Role: CONTACT

dietaryUCTrial@partners.org

(617) 732-9110

Facility Contacts

Justine States

Role: primary

dietaryUCTrial@partners.org

617-732-9110

Other Identifiers

TLS-UC-003

Identifier Type: -

Identifier Source: org_study_id